Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4 USD | -2.20% | +6.38% | +15.94% |
Mar. 21 | Xenetic Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 18 | CLS Therapeutics Discloses its Views on Xenetic Biosciences | CI |
Sales 2024 * | 2.13M 2.68M | Sales 2025 * | 1.42M 1.78M | Capitalization | 5.02M 6.31M |
---|---|---|---|---|---|
Net income 2024 * | -4M -5.02M | Net income 2025 * | -8M -10.05M | EV / Sales 2024 * | 2.36 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 3.53 x |
P/E ratio 2024 * |
-1.17
x | P/E ratio 2025 * |
-4.88
x | Employees | 4 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 80.81% |
1 day | -2.20% | ||
1 week | +3.90% | ||
Current month | +6.10% | ||
1 month | -4.76% | ||
3 months | +13.31% | ||
6 months | +23.84% | ||
Current year | +15.94% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 58 | 16-07-10 | |
James F. Parslow
DFI | Director of Finance/CFO | 59 | 17-04-02 |
Curtis Lockshin
CTO | Chief Tech/Sci/R&D Officer | 64 | 14-02-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 58 | 16-07-10 | |
Moshe Mizrahy
BRD | Director/Board Member | 71 | - |
Adam Logal
CHM | Chairman | 46 | 17-08-13 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-29 | 4 | -2.20% | 3,998 |
24-04-26 | 4.09 | +8.32% | 667 |
24-04-25 | 3.776 | -1.92% | 1,657 |
24-04-23 | 3.85 | +2.39% | 2,719 |
Delayed Quote Nasdaq, April 29, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+15.94% | 6.3M | |
-2.63% | 103B | |
+1.62% | 95.28B | |
+1.46% | 22.15B | |
-16.67% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.21% | 16.05B | |
+5.41% | 13.68B | |
+33.57% | 12.17B |
- Stock Market
- Equities
- XBIO Stock